Floxuridine
- Generic Name
- Floxuridine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11FN2O5
- CAS Number
- 50-91-9
- Unique Ingredient Identifier
- 039LU44I5M
- Background
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gas...
- Indication
For palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Also for the palliative management of liver cancer (usually administered by hepatic intra-arterial infusion).
- Associated Conditions
- Stage 4 gastrointestinal adenocarcinoma
- Associated Therapies
- Palliative Treatment
Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2020-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT01749397
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 27
- Registration Number
- NCT01525069
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
- Conditions
- Interventions
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2018-01-08
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 8
- Registration Number
- NCT00848783
- Locations
- 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸NYU Cancer Center, New York, New York, United States
🇺🇸Norris Cancer Center, Los Angeles, California, United States
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
- Conditions
- Interventions
- Drug: gemcitabine hydrochlorideDrug: floxuridineGenetic: proteomic profilingOther: matrix-assisted laser desorption/ionization time of flight mass spectrometryOther: liquid chromatographyRadiation: yttrium Y 90 anti-CEA monoclonal antibody cT84.66Other: laboratory biomarker analysisOther: mass spectrometryOther: pharmacological study
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT00645710
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy
- First Posted Date
- 2008-01-07
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00587067
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT00492999
- Locations
- 🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States
Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 29
- Registration Number
- NCT00448760
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 25
- Registration Number
- NCT00448682
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 25
- Registration Number
- NCT00449163
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
- Conditions
- Locations
- 🇺🇸
Surgery Branch, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.